Lawrence Lin is a seasoned executive with over two decades of experience in the life sciences and technology sectors. He currently serves as Executive Vice President and Chief Executive Officer of AZENTA INC., a leading provider of innovative solutions for sample management, genomics, and cryogenic storage in the biotechnology industry. Lin's journey began with a strong academic foundation, holding a Bachelor's degree in Biomedical Engineering from Stanford University and an MBA from Harvard Business School. Early in his career, he honed his skills at prominent firms like Thermo Fisher Scientific and PerkinElmer, where he led teams in developing cutting-edge laboratory automation systems that streamlined research processes for pharmaceutical companies worldwide. Throughout his professional trajectory, Lin has been recognized for his strategic vision and ability to drive growth in competitive markets. At PerkinElmer, he spearheaded the acquisition and integration of several startups, resulting in a 40% increase in market share for diagnostic tools. His leadership in AZENTA's predecessor company, Brooks Automation, was instrumental in pivoting the organization toward life sciences, culminating in the successful rebranding to AZENTA INC. in 2022. Lin's achievements include numerous industry awards, such as the Biotech Innovation Award in 2020, and he is a frequent speaker at global conferences on the future of precision medicine and AI-driven lab solutions. In his current role at AZENTA INC., Lin oversees all aspects of the company's operations, from research and development to global sales and partnerships. Under his guidance, AZENTA has expanded its portfolio to include advanced genomic services and sustainable cryogenic technologies, positioning the company as a key player in supporting drug discovery and personalized medicine. Lin is committed to fostering a culture of innovation and inclusivity, emphasizing ethical practices and sustainability in biotechnology. His forward-thinking approach continues to propel AZENTA toward new heights, ensuring it remains at the forefront of enabling breakthroughs in life sciences.